PLASMA THERAPY MARKET ANALYSIS

Market News

Global Plasma Therapy Market: Key Developments

On August 24, 2020, the Food and Drug Administration (U.S. FDA) approved the convalescent plasma therapy for treatment of Covid–19 patients in the U.S., without completing the clinical trial due to the exponential increase in the coronavirus infected patients. Convalescent plasma therapy uses blood from people who have recovered from the coronavirus infection to help others recover.  

On 3 June 2020, researchers from the Houston Methodist Hospital- a U.S.-based health care system and academic center, initiated clinical trials for recording efficacy of the plasma therapy when plasma is transfused from recovered Covid-19 patients into critically ill patients. According to the researchers, 19 out of 25 patients were showing signs of recovery post plasma therapy and 11 patients were later discharged from the hospital following recovery.

On 7th April 2020, Takeda Pharmaceutical Company Limited, a Japan-based multinational biopharmaceutical company and CSL, a pharmaceutical company, collaboratively developed a new treatment for patients suffering from the coronavirus infection. The treatment plan involves using blood plasma of patients who have recovered from the infection by further isolating the antibodies from the plasma and injecting it in patients. This therapy triggers an immune response in the body of the patients which can help them survive the infection.

On 30th June 2020, the Government of Maharashtra, a state in India, launched Platina, a clinical trial for treatment of COVID-19 patients. The project aims to provide free plasma therapy at 21 government centers in Maharashtra to increase the chances of survival of the infected patients. The government is also spreading awareness among recovered patients regarding plasma donation so that the plasma can be processed and utilized for therapy.